AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16286279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency of right IMA anastomosis with or without off-pump technique in Group B
Number of subjects: 94
Study 12036167 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 406
Study 12036167 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 406
Study 12036167 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 10 mg/Acetaminophen 1,000 mg
Number of subjects: 406
Study 12036167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 10440879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy after transurethral resection
Number of subjects: 0
Study 7598072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (70g carbohydrate/d)
Number of subjects: 48
Study 7598072 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet (10g carbohydrate/d)
Number of subjects: 48
Study 7598072 — intervention group
Group type: EXPERIMENTAL
Intervention: 50g protein/d
Number of subjects: 48
Study 7598072 — intervention group
Group type: EXPERIMENTAL
Intervention: 70g protein/d
Number of subjects: 48
Study 3135609 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 g of pivampicillin plus 1.0 g of probenecid, taken once a day for five days
Number of subjects: 119
Study 3135609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole (400 mg) and trimethoprim (80 mg), single ten-tablet dose on the first day, two five-tablet doses on the second day, and two three-tablet doses for the next three to five days
Number of subjects: 119
Study 3135609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole (400 mg) and trimethoprim (80 mg), single ten-tablet dose on the first day and two five-tablet doses on the second day
Number of subjects: 119
Study 31392896 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision-related Mobility
Number of subjects: 186
Study 31392896 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision-related Reading
Number of subjects: 186
Study 31392896 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision-related Emotional
Number of subjects: 186
Study 31657165 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) applied to Dazhui (GV14) and Mingmen (GV4) for 30 min at 2 Hz/100 Hz, 20‐30 mA.
Number of subjects: 80
Study 31657165 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) group.
Number of subjects: 80
Study 31657165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electrical current transmission).
Number of subjects: 80
Study 28177209 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-term preventive labor induction
Number of subjects: 279
Study 28177209 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 279
Study 26423742 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs) 500 kcal/d
Number of subjects: 1967
Study 26423742 — intervention group
Group type: COMPARATOR
Intervention: Super Cereal Plus (SC+) 810 kcal/d
Number of subjects: 1967
Study 21942363 — intervention group
Group type: COMPARATOR
Intervention: Immediate dental implants without any filling material around the implants (Group A)
Number of subjects: 28
Study 21942363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure-phase multiporous beta-tricalcium phosphate (beta-TCP) packed into the bone gaps around the implants (Group B)
Number of subjects: 28
Study 21293921 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant surgical oophorectomy during the luteal phase of the menstrual cycle
Number of subjects: 0
Study 21293921 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant surgical oophorectomy during the follicular phase of the menstrual cycle
Number of subjects: 0
Study 18445665 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (66 microg/kg.d) for 2 years in group 3 (78 patients from group 1)
Number of subjects: 219
Study 18445665 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1 and group 2 without GH therapy)
Number of subjects: 219
Study 20069533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST), a 14-session group treatment
Number of subjects: 0
Study 20069533 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study 16101937 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Lactobacillus paracasei (LP33) - 5 x 10(9) colony-forming units/capsule, 2 capsules per day for 30 days
Number of subjects: 90
Study 16101937 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus paracasei (LP33) - 5 x 10(9) colony-forming units/capsule, 2 capsules per day for 30 days
Number of subjects: 90
Study 16101937 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 2 capsules per day for 30 days
Number of subjects: 90
Study 12468781 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral citicoline (500, 1000, and 2000 mg)
Number of subjects: 1372
Study 12468781 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral citicoline (2000 mg)
Number of subjects: 1372
Study 12468781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1372
Study 9740631 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously immobilized limb after plaster removal
Number of subjects: 7
Study 9740631 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously immobilized limb after 45 days of rehabilitation
Number of subjects: 7
Study 9740631 — intervention group
Group type: COMPARATOR
Intervention: Contralateral limb after plaster removal
Number of subjects: 7
Study 9740631 — intervention group
Group type: COMPARATOR
Intervention: Contralateral limb after 45 days of rehabilitation
Number of subjects: 7
Study 8067216 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural analgesia with bupivacaine 5 mg.ml‐1 and 5 microgram epinephrine, 30 ml bolus, continuous infusion at 7 ml/hour
Number of subjects: 32
Study 8067216 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia with bupivacaine 3.75 mg.ml‐1 and 5 microgram epinephrine, 5 ml bolus, continuous infusion at 5 ml/hour
Number of subjects: 32
Study 3289648 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 4 mg/day
Number of subjects: 102
Study 3289648 — intervention group
Group type: COMPARATOR
Intervention: Chlormethiazole 3.072 g/day (equivalent to 8 g of the edisylate)
Number of subjects: 102
Study 11399715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediflo spirometer (high WBimp)
Number of subjects: 30
Study 11399715 — intervention group
Group type: COMPARATOR
Intervention: Coach spirometer (low WBimp)
Number of subjects: 30
Study 30683060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist's medication review combined with a communication pathway to GPs and nursing home staff, facilitation of change in interprofessional cooperation, educational training, and a toolbox for implementation.
Number of subjects: 760
Study 30683060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist's medication review and interprofessional cooperation measures.
Number of subjects: 760
Study 29317015 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP BAI 320 μg/day
Number of subjects: 425
Study 29317015 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP BAI 640 μg/day
Number of subjects: 425
Study 29317015 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP MDI 320 μg/day
Number of subjects: 425
Study 29317015 — intervention group
Group type: COMPARATOR
Intervention: Placebo BAI
Number of subjects: 425
Study 29317015 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 425
Study 25037985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive supervision of physiotherapist for 1 month (2 days/week) - Group 1
Number of subjects: 60
Study 25037985 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of physiotherapist twice monthly (1 day/2 weeks) - Group 2
Number of subjects: 60
Study 25037985 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals - Group 3
Number of subjects: 60
Study 25405392 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 608
Study 25405392 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 608
Study 21667048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Care Intervention (CCI) plus usual care (n = 118)
Number of subjects: 237
Study 21667048 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (n = 119)
Number of subjects: 237
Study 21667048 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 237
Study 21667048 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, stage of cancer, and surgical removal of the tumor
Number of subjects: 237
Study 21667048 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc analysis by cancer site and gender
Number of subjects: 237
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 IU recombinant follicle-stimulating hormone (rFSH)/day
Number of subjects: 123
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing pregnancy
Number of subjects: 123
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with age
Number of subjects: 123
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with antral follicle count (AFC)
Number of subjects: 123
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with ovarian volume
Number of subjects: 123
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with FSH
Number of subjects: 123
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with cycle length
Number of subjects: 123
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 123
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 123
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral follicle count (AFC)
Number of subjects: 123
Study 20303323 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH
Number of subjects: 123
Study 17354182 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hypertonic glucose solution injections
Number of subjects: 67
Study 17354182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 67
Study 17354182 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 67
Study 17354182 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 15371046 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin bath treatment combined with hand exercise
Number of subjects: 17
Study 15371046 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (Control)
Number of subjects: 17
Study 11591551 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (two 200-microg puffs bid; budesonide group, n = 19)
Number of subjects: 37
Study 11591551 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo (placebo group, n = 18)
Number of subjects: 37
Study 11591551 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (symptomatic group, n = 19)
Number of subjects: 37
Study 9845852 — intervention group
Group type: COMPARATOR
Intervention: Placebo and US National Cholesterol Education Program step 1 diet
Number of subjects: 215
Study 9845852 — intervention group
Group type: COMPARATOR
Intervention: Placebo and step 2 diet
Number of subjects: 215
Study 9845852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg day‐1 and step 1 diet
Number of subjects: 215
Study 9845852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg day‐1 and step 2 diet
Number of subjects: 215
Study 7990319 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐activin
Number of subjects: 182
Study 7990319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no T‐activin)
Number of subjects: 182
Study 3058228 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) for 10 or 28 days in Group I (77 patients with acute severe aplastic anemia)
Number of subjects: 150
Study 3058228 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) for 10 days in Group II (44 patients with moderate or chronic severe aplastic anemia)
Number of subjects: 150
Study 3058228 — intervention group
Group type: COMPARATOR
Intervention: High-dose nandrolone decanoate for 3 months in Group II (44 patients with moderate or chronic severe aplastic anemia)
Number of subjects: 150
Study 3058228 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) in Group III (patients with various bone marrow failure syndromes)
Number of subjects: 150
Study 30099209 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered pain management program (Pain Course) with clinician support
Number of subjects: 490
Study 30099209 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 490
Study 28238465 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 2448
Study 26165391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/Famotidine (800 mg ibuprofen and 26.6 mg famotidine, three times daily)
Number of subjects: 0
Study 26165391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/Famotidine
Number of subjects: 0
Study 26165391 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 23794693 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask
Number of subjects: 47
Study 23794693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue Plate
Number of subjects: 47
Study 23794693 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 47
Study 21048773 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut supplementation (15 g/day for 4 weeks)
Number of subjects: 30
Study 21048773 — intervention group
Group type: COMPARATOR
Intervention: Control (no walnuts for 4 weeks)
Number of subjects: 30
Study 18281378 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa+E(2)
Number of subjects: 10
Study 18281378 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa+E(2)+MPA
Number of subjects: 10
Study 18281378 — intervention group
Group type: COMPARATOR
Intervention: GnRHa
Number of subjects: 10
Study 16569732 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg/d)
Number of subjects: 37
Study 16569732 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg/d)
Number of subjects: 37
Study 12867226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg alone
Number of subjects: 18
Study 12867226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg with alcohol (0.3 g/kg body weight)
Number of subjects: 18
Study 12867226 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 50 mg
Number of subjects: 18
Study 12867226 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 50 mg with alcohol
Number of subjects: 18
Study 12867226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10559084 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg qd for 8 weeks
Number of subjects: 107
Study 10559084 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 107
Study 8559161 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with median mononeuropathy (MM)
Number of subjects: 414
Study 8559161 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MM and type II diabetes
Number of subjects: 414
Study 8559161 — intervention group
Group type: COMPARATOR
Intervention: Sural or peroneal conduction abnormalities
Number of subjects: 414
Study 1872197 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine acetate medicated Multiload MLCu250 IUD
Number of subjects: 29
Study 1872197 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload MLCu250 IUD
Number of subjects: 29
Study 1872197 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IUD)
Number of subjects: 29
Study 6605682 — intervention group
Group type: COMPARATOR
Intervention: Fenbufen (600 or 900 mg daily)
Number of subjects: 50
Study 6605682 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3.6 g daily)
Number of subjects: 50
Study 6605682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30758216 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-Curcuminoid mouthwash (CHI-CUR)
Number of subjects: 30
Study 30758216 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash (CHX)
Number of subjects: 30
Study 30758216 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle formulation (chitosan and PEG 400)
Number of subjects: 30
Study 27585808 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help intervention (based on problem-solving therapy)
Number of subjects: 16
Study 26470874 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ascending doses of 20(S)-ginsenoside Rg3 (10-60 mg)
Number of subjects: 33
Study 26470874 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 20(S)-ginsenoside Rg3 (30 mg for 15 days)
Number of subjects: 33
Study 25093627 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery group
Number of subjects: 0
Study 25093627 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22747890 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Number of subjects: 60
Study 22747890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 60
Study 22747890 — intervention group
Group type: COMPARATOR
Intervention: Preoperative fasting
Number of subjects: 60
Study 19622526 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular warm-up programme (1-3 times per week for 6 months, 25 min per session)
Number of subjects: 222
Study 17612905 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tablet combination therapy
Number of subjects: 10704
Study 15364437 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week vaccination schedule (0, 1, 3 weeks) with 20microg Engerix B i.m.
Number of subjects: 585
Study 15364437 — intervention group
Group type: COMPARATOR
Intervention: 6-month vaccination schedule (0, 1, 6 months) with 20microg Engerix B i.m.
Number of subjects: 585
Study 11739118 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 24
Study 11739118 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion
Number of subjects: 24
Study 11739118 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 24
Study 10408547 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid
Number of subjects: 227
Study 10408547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 7487853 — intervention group
Group type: EXPERIMENTAL
Intervention: High Responsibility (HR) group
Number of subjects: 0
Study 7487853 — intervention group
Group type: COMPARATOR
Intervention: Low Responsibility (LR) group
Number of subjects: 0
Study 2248077 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 300‐500 mg daily for 4 weeks
Number of subjects: 119
Study 2248077 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 150‐300 mg daily for 6 weeks
Number of subjects: 119
Study 2248077 — intervention group
Group type: COMPARATOR
Intervention: Mianserin 75‐125 mg daily for 4 weeks
Number of subjects: 119
Study 2248077 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline 75‐150 mg daily for 6 weeks
Number of subjects: 119
Study 7248705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled irrigating fluid at 8 degrees C
Number of subjects: 40
Study 7248705 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature irrigating fluid
Number of subjects: 40
Study 29659888 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg daily
Number of subjects: 46
Study 29659888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26490018 — intervention group
Group type: COMPARATOR
Intervention: Probiotic drink containing Lactobacillus casei Shirota, administered twice a day for 4 weeks.
Number of subjects: 71
Study 26490018 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink, administered for 4 weeks.
Number of subjects: 71
Study 24626000 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophyline (4 mg/kg IV loading dose, followed by 200 mg orally three times daily for four days)
Number of subjects: 76
Study 24626000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 20550483 — intervention group
Group type: EXPERIMENTAL
Intervention: Orodispersible tablets (ODTs) incorporating PEG solid dispersion of meloxicam (MLX)
Number of subjects: 0
Study 20550483 — intervention group
Group type: COMPARATOR
Intervention: Marketed immediate release MLX tablet
Number of subjects: 0
Study 20386003 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced depression treatment (problem-solving therapy and/or pharmacotherapy, then a stepped-care approach)
Number of subjects: 237
Study 20386003 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced depression treatment
Number of subjects: 237
Study 20386003 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 237
Study 18451780 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (Xenical) for 6 months
Number of subjects: 95
Study 18451780 — intervention group
Group type: COMPARATOR
Intervention: No specific medication (Control)
Number of subjects: 95
Study 16170170 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of plasma total carotenoid concentration
Number of subjects: 1551
Study 12952293 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 Pseudomonas exotoxin (NBI-3001) administered intratumorally via convection-enhanced delivery at doses of 6 microg/ml x 40 ml, 9 microg/ml x 40 ml, 15 microg/ml x 40 ml, or 9 microg/ml x 100 ml.
Number of subjects: 31
Study 11028576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injection
Number of subjects: 100
Study 11028576 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection
Number of subjects: 100
Study 8630719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg qd
Number of subjects: 311